RASSF1 and colorectal carcinoma: RASSF1A promoter methylation was reported as a prognostic biomarker in patients with stage II and III CRC receiving oxaliplatin‐based chemotherapy, when investigated by MSP in 108 CRC patients before and after chemotherapy and 78 healthy controls [77].